Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment Diamyd Medical has entered into financing agreements with U.S. investors totaling $125 million and announced full enrollment in its Phase 3 trial.

Diamyd Medical Secures Up to $125 Million in Equity Financing and Completes Phase 3 Trial Enrollment #Sweden #Stockholm #Diamyd_Medical #Phase_3_Trial #retogatein

Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion Diamyd Medical announces successful financing agreements totaling $125 million and the completion of its Phase 3 clinical trial for Type 1 diabetes.

Diamyd Medical Secures $125 Million in Financing Amid Phase 3 Trial Completion #Sweden #Stockholm #Diamyd_Medical #Phase_3_Trial #retogatein

Diamyd Medical's Phase 3 DIAGNODE-3 Trial Database Finalized for Interim Analysis Diamyd Medical has successfully completed the clinical database for the interim analysis in its Phase 3 trial, DIAGNODE-3, assessing retogatein for type 1 diabetes treatment.

Diamyd Medical's Phase 3 DIAGNODE-3 Trial Database Finalized for Interim Analysis #Sweden #Stockholm #Diamyd_Medical #DIAGNODE-3 #retogatein

Diamyd Medical Gains Significant Patent Notice for Retogatein in the U.S. Diamyd Medical recently announced a vital patent allowance from the USPTO for retogatein, marking progress in its diabetes treatment efforts.

Diamyd Medical Gains Significant Patent Notice for Retogatein in the U.S. #USA #Stockholm #Type_1_Diabetes #Diamyd_Medical #retogatein

Diamyd Medical Secures Key Patent Allowance for Retogatein in the US Market Diamyd Medical has received a Notice of Allowance from the USPTO for a patent on retogatein, an important immunotherapy for type 1 diabetes.

Diamyd Medical Secures Key Patent Allowance for Retogatein in the US Market #USA #Stockholm #Type_1_Diabetes #Diamyd_Medical #retogatein